Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 5Breast Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × NVP-BKM120 × Gastrointestinal × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡